Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

Mette T. Mouritzen, Andreas Carus, Morten Ladekarl, Peter Meldgaard, Anders W. M. Nielsen, Anna Livbjerg, Jacob W. Larsen, Halla Skuladottir, Charlotte Kristiansen, Kim Wedervang, Tine Schytte, Karin H. Hansen, Anne-Cathrine Østby, Malene S. Frank, Jakob Lauritsen, Jens B. Sørensen, Seppo W. Langer, Gitte F. Persson, Jon L Andersen, Johanna M. C. FraryLars B. Drivsholm, Charles Vesteghem, Heidi S. Christensen, Birgitte Bjørnhart, Mette Pøhl

Research output: Contribution to journalJournal articleResearchpeer-review

2 Citations (Scopus)
12 Downloads (Pure)
Original languageEnglish
Article number4846
JournalCancers
Volume13
Issue number19
ISSN2072-6694
DOIs
Publication statusPublished - 28 Sep 2021

Keywords

  • Advanced lung cancer
  • Anti-PD-1
  • Cancer immunotherapy
  • Clinical prognostic factors
  • Danish registry
  • First-line treatment
  • Immune checkpoint inhibitors
  • Non-small cell lung cancer
  • Overall survival
  • Real-world evidence

Fingerprint

Dive into the research topics of 'Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy'. Together they form a unique fingerprint.

Cite this